LeonaBio (LONA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 Jun, 2026Opening remarks and agenda
Meeting called to order by the Chairperson, with all board members and senior management introduced.
Independent auditor, legal counsel, and Inspector of Election introduced; meeting procedures outlined.
Agenda included voting on proposals as described in the proxy statement dated May 11, 2026.
Board and executive committee updates
Three Class III directors nominated for election to serve until the 2029 Annual Meeting.
All nominees confirmed their willingness to serve if elected.
Shareholder proposals
No shareholder proposals were submitted in accordance with advance notice provisions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from LeonaBio
- Virtual annual meeting to vote on directors, auditor, and executive pay, all board-recommended.LONA
Proxy filing11 May 2026 - Proxy covers director elections, auditor ratification, compensation, and ESG oversight.LONA
Proxy filing11 May 2026 - Q1 2026 net loss rose to $32.9M as R&D spending increased; cash covers 12 months, more funding needed.LONA
Q1 20267 May 2026 - Lasofoxifene plus abemaciclib shows strong promise for ESR1-mutated metastatic breast cancer.LONA
Status update30 Apr 2026 - Registering 5.5M shares for resale; proceeds from warrant exercise support drug pipeline.LONA
Registration filing31 Mar 2026 - 58.5M shares registered for resale; warrant exercises could yield over $146M for clinical programs.LONA
Registration filing31 Mar 2026 - Secured lasofoxifene license, raised $90M, and advanced clinical pipeline amid higher R&D spend.LONA
Q4 202526 Mar 2026 - All proposals, including key share issuances and governance changes, were approved by majority vote.LONA
EGM 202618 Mar 2026 - Proposal 6 is now routine, enabling discretionary broker voting at the March 2026 meeting.LONA
Proxy Filing10 Mar 2026